Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776019 | 0.89 | FGFR4 (0.42) | CNR1ADORA2AUSP30LRRK2GRM5 | |
| SCHEMBL20632365 | 0.86 | FAAH (0.37) | FAAHSIRT2CNR1ADORA2AUSP30 | |
| SCHEMBL16776096 | 0.86 | USP30 (0.39) | SIRT2ADORA2AUSP30LRRK2FGFR4 | |
| SCHEMBL16775832 | 0.86 | FAAH (0.40) | FAAHSIRT2CNR1ADORA2A | |
| SCHEMBL16776094 | 0.86 | GRM5 (0.42) | FAAHUSP30LRRK2GRM5FGFR4 | |
| SCHEMBL16775865 | 0.85 | FAAH (0.47) | FAAHSIRT2 | |
| SCHEMBL16776097 | 0.85 | HTR2C (0.45) | CNR1GRM5CYP11B2 | |
| SCHEMBL16776021 | 0.84 | FGFR4 (0.42) | USP30FGFR4 | |
| SCHEMBL16776162 | 0.84 | FAAH (0.37) | FAAHFGFR4 | |
| SCHEMBL16775817 | 0.83 | FAAH (0.40) | FAAHSIRT2CNR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 977/4885SIRT2 3/4885CNR1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.